Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that has been shown to be overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Product Name:
Human c-MET/HGFR Recombinant Protein (RPES1693)
Product Code:
RPES1693
Size:
20µg
Species:
Human
Expressed Host:
Baculovirus-Insect Cells
Synonyms:
AUTS9,c-Met,DFNB97,HGFR,RCCP2
Accession:
P08581-1
Sequence:
Lys956-Ser1390
Fusion tag:
N-His & GST
Activity:
The specific activity was determined to be 10 nmol/min/mg using MBP as substrate.2. Measured by its binding ability in a functional ELISA. Immobilized human HGFR (aa 956-1390) at 10 µg/ml (100 ?l/well) can bind biotinylated human HGF-his with a linear range of 15.6-125 ng/ml.
Endotoxin:
<1.0 EU per µg as determined by the LAL method.
Protein Construction:
A DNA sequence encoding the human MET (P08581-1) (Lys956-Ser1390) was fused with the N-terminal polyhistidine-tagged GST tag at the N-terminus.
